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Abstract
Atherosclerotic plaque disruption does not always result in acute symptomatic events.
Therefore, the formation of a large thrombus is a critical step in the development of athe‐
rothrombosis. However, little is known about the mechanisms involved in thrombus
growth processes after plaque disruption. Studies in vivo have demonstrated that the tis‐
sue factor (TF) derived from the vascular wall contributes to the formation of thrombin-
dependent platelet–fibrin thrombus on atherosclerotic arteries but not on normal arteries,
and that altered blood flow in disrupted atherosclerotic arteries promotes platelet recruit‐
ment mediated by von Willebrand factor (VWF) on the thrombus surface and augmented
blood coagulation resulting in thrombus growth. The thrombogenic potential of plaques
is a fundamental factor in atherothrombosis. We recently found that the arterial glucose
uptake reflects vascular thrombogenicity, which might be partly explained by metabolic
adaptation and enhanced procoagulant activity in a hypoxic microenvironment. Hypoxic
responses might link atherometabolism to vascular thrombogenicity.
Keywords: Atherometabolism, hypoxia, plaque erosion, thrombus growth, plaque
thrombogenicity
1. Introduction
Thrombus formation on a ruptured or an eroded atherosclerotic plaque is a critical event that
leads to atherothrombosis. However, autopsy studies have identified asymptomatic coronary
thrombi on disrupted plaques and pathological differences in plaques with symptomatic and
asymptomatic thrombi [1, 2]. Therefore, plaque disruption is not a final step, whereas throm‐
bus growth processes are critical for the development of atherothrombosis. Despite intensive
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investigation into the mechanisms of atherogenesis and plaque instability [3], little is known
about the mechanisms involved in thrombus growth after plaque disruption. Vascular
thrombogenicity and changes in blood flow and blood factors are generally thought to regulate
thrombus formation. Therefore, disparities in these regulators affect the thrombus growth, and
atherosclerotic plaque thrombogenicity is an essential factor for atherothrombosis. Plaque
vulnerability, the upregulation of prothrombotic factors, and the downregulation of antith‐
rombotic factors in atherosclerotic plaques have been demonstrated [3–5], and inflammatory
stimuli play important roles in plaque thrombogenicity [6]. However, the determinants of
vascular wall thrombogenicity are not fully understood.
Arterial inflammation has been evaluated using positron emission tomography (PET) imaging
with [18F]-fluorodeoxyglucose (18F-FDG). The close correlation between 18F-FDG uptake and
plaque macrophage contents in animal models of atherosclerosis [7] suggests that the degree
of 18F-FDG reflects the underlying levels of vascular inflammation. Clinical studies have
identified a relationship between 18F-FDG uptake and numbers of cardiovascular risk factors,
as well as risk for future events [8, 9]. The uptake of 18F-FDG is significantly higher in aortic
segments with thrombus than without thrombus in a rabbit model of advanced atherosclerosis
[10]. These lines of evidence imply an association between glucose uptake and vascular
thrombogenicity, although the underlying mechanism is unknown.
This article focuses on the pathophysiology of thrombus growth on disrupted plaques and
discusses a conceivable relationship between atherometabolism and vascular thrombogenic‐
ity.
2. Pathology of atherothrombosis
Arterial thrombi are mainly composed of aggregated platelets as a likely result of rapid blood
flow, and the development of platelet-rich thrombi is regarded as a cause of atherothrombosis.
Fresh coronary thrombi in patients with acute myocardial infarction (AMI) and unstable
angina have become assessable due to technological advances, distal protection, and thrombus
aspiration devices. Evidence gathered from such studies indicates that such fresh athero‐
thrombi consist of aggregated platelets, fibrin, erythrocytes, and white blood cells comprising
mostly neutrophils, and that they are constitutively immunopositive for the platelet integrin
αIIbβ3, fibrin, the membrane protein expressed on erythrocytes glycophorin A, and the von
Willebrand factor (VWF; blood adhesion molecule). VWF and tissue factor (TF; initiator of the
coagulation cascade) are closely associated with integrin αIIbβ3 and fibrin, respectively [11,
12] (Figure 1). These findings suggest that the enhanced platelet aggregation and fibrin
formation result in thrombus growth and obstructive thrombus formation on disrupted
atherosclerotic plaques, and that VWF and/or TF contribute to the pathological process.
Pathological findings suggest that plaque disruption and sudden coronary occlusion are often
preceded by a variable period of thrombus formation. Aspirated thrombi from one-third to
half of patients with AMI show cell lytic changes and/or organizing reactions, namely
endothelialization with or without smooth muscle cell (SMC) ingrowth [13, 14] (Figure 2).
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These findings indicate that the thrombi are aged more than several days after formation. In
addition, organizing thrombus is associated with the in-hospital and long-term mortality of
patients with AMI [14, 15].
Plaques become disrupted via rupture and erosion. Plaques rupture when a thin fibrous cap
ruptures, which allows blood to come in contact with a thrombogenic necrotized core, resulting
in thrombus formation. A ruptured plaque is characterized by disrupted thin fibrous caps,
usually < 65 μm thick, abundant macrophages and lymphocytes, and a few SMCs [16]. Thus,
a thinning fibrous cap is thought to represent a state that is vulnerable to rupture, which is
referred to as thin-cap fibroatheroma [17]. However, this is not taken into account in the current
αIIbβ3 Fibrin Merge
FibrinTF Merge
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Figure 1. Immunofluorescence micrographs of fresh coronary thrombi in patients with acute myocardial infarction.
Left, staining with fluorescein isothiocyanate-labeled integrin αIIbβ3, VWF, and TF (green). Center, staining with Cy3
labeled with fibrin and VWF (red). Right, merged immunofluorescence images. Areas of colocalized factors are stained
yellow. Atherothrombus comprises platelets and fibrin. VWF and TF are closely associated with αIIbβ3 and fibrin, re‐
spectively. TF, tissue factor; VWF von Willebrand factor (from Ref. 11 with permission).
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American Heart Association classification of atherosclerosis. Plaques undergoing erosion are
characterized by a denuded surface and thrombus formation, and lack a disrupted fibrous cap.
Patients with plaque erosion are younger and are not predominantly males compared with
those who have ruptured plaques. Angiography has shown that the luminal surface of eroded
plaques is less narrowed and irregular. The morphological features include abundant SMCs
and proteoglycan matrix, especially versican and hyaluronan, and disrupted surface endo‐
thelium. An eroded plaque contains relatively few macrophages and T cells compared with a
ruptured plaque [16]. In contrast, macrophages comprise the dominant cell type at sites of both
plaque rupture and erosion, and both inflammatory cells and SMCs express human leukocyte
antigen (HLA-DR) antigens [18]. These findings suggest that eroded plaques are heterogene‐
ous and that both inflammatory and noninflammatory processes contribute to the develop‐
ment of plaque erosion. The proportions of fibrin and platelets differ in coronary thrombi on
ruptured and eroded plaques. Thrombi on ruptured and eroded plaques are rich in fibrin and
platelets, respectively. The tissue factor is abundant in a ruptured plaque compared with an
eroded plaque [19]. These characteristics of ruptured and eroded plaques (abundant TF,
phospholipids, and less matrix protein in ruptured sites; abundant matrix protein and less TF
in eroded sites) might explain the difference in the composition of thrombi in ruptured and
eroded plaques.
3. Pathology of asymptomatic plaque disruption
Clinical angioscopy studies have revealed that asymptomatic multiple plaque rupture is a
frequent complication among patients with coronary atherothrombosis [20]. Various stages of
healed plaque disruption are also occasionally found during autopsies of individuals with and
without known coronary atherothrombosis [2, 21]. Hearts at autopsy from patients who died
Figure 2. Light and immunohistochemical images of acute coronary thrombi in patients with acute myocardial in‐
farction. Thrombus comprises degraded erythrocytes and leukocytes, mononuclear cell infiltrate, and small luminal
structures lined with flat or spindle cells. CD34 immunostaining highlights endothelialization and microvessel forma‐
tion in the thrombus, indicating organized reaction, even acute onset of AMI. HE, hematoxylin eosin stain.
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of AMI have been compared with hearts form those who succumbed to noncardiac death to
determine the incidence and morphological characteristics of thrombi and plaque disruption
in patients with noncardiac death [1]. This study found coronary thrombi in 16% of noncardiac
deaths; most of them had developed an eroded plaque and were too small to affect the coronary
lumen (Figure 3). Smaller lipid areas, thicker fibrous caps, and more modest luminal narrowing
were features of disrupted plaques associated with noncardiac death compared with AMI.
Davies et al. [21] and Arbustini et al. [22] found coronary thrombus in 4% and 7% of noncardiac
deaths, respectively, at autopsy. The coronary thrombi from noncardiac deaths were associ‐
ated with eroded plaques [22]. These results suggest that plaque disruption does not always
result in complete thrombotic occlusion with subsequent acute symptomatic events, and that
thrombus growth is a critical step in the onset of clinical events. However, the determinants
of coronary thrombus size after plaque disruption remain unknown.
The histological assessment of 157 carotid endarterectomy samples from asymptomatic
patients and those with symptomatic major stroke revealed less frequent erosion in both
symptomatic (3.1%) and asymptomatic plaques (6.7%) [23]. Less disrupted plaques, fewer
inflammatory cells, a smaller necrotic core, and more calcification were identified in throm‐
botic plaques from the asymptomatic patients [23]. Because information about asymptomatic
plaque disruption is limited, the features of coronary and carotid plaques are not identical.
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Figure 3. Coronary plaque erosion in patients with noncardiac death.  
 
Superficial erosive injury and mural thrombus (arrows) are evident on atherosclerotic lesions. A thrombus is too small to obstruct the 
coronary lumen and induce symptomatic events. HE, hematoxylin eosin stain (from Ref. 1, with permission). 
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Eroded plaque is characterized by a superficial plaque injury, but the mechanisms of such erosions are poorly understood. 
Approximately 80% thrombi associated with plaque erosion is nonocclusive regardless of sudden coronary death [16]. Experimental 
aortic stenosis can induce acute endothelial changes or damage to the normal aorta [24]. Therefore, hemodynamic forces, particularly 
those generated by disturbed blood flow induced by stenosis or vasoconstriction, could be a crucial factor in generating surface 
vascular damage and thrombosis. We investigated pathological changes after acute luminal narrowing in SMC-rich plaques in rabbits 
to understand the relationship between disturbed blood flow and plaque erosion. Balloon-induced injury of rabbit femoral arteries 
resulted in the formation of SMC-rich plaques comprising stellate- or spindle-shaped SMCs and extracellular matrix [25]. Acute 
vascular narrowing disrupted the blood flow in these arteries that consequently induced superficial erosive injury of the SMC-rich 
plaque. Figure 4 shows microscopic images of a longitudinal section of neointima at the post-stenotic region 15 min after vascular 
narrowing. The endothelial cells and SMCs at this region are broadly detached and associated with platelet adhesion to the 
subendothelium and a change in the shape of the SMCs. Endothelial cells and superficial SMCs became apoptotic within 15 min [26]. 
Subsequent vascular narrowing induced mural thrombi comprising platelets and fibrin, as in human plaque erosion. Thus, disrupted 
Figure 3. Coronary plaque erosion in patients with noncardiac death. Superficial erosive injury and mural thrombus
(arrows) are evident on atherosclerotic lesions. A thrombus is too small to obstruct the coronary lumen and induce
symptomatic events. HE, hematoxylin eosin stain (from Ref. 1, with permission).
4. Pathophysiology of atherothrombosis
Atherothrombosis is initiated by plaque rupture or erosion. Accumulating evidence supports
the notion that inflammation and matrix degradation contribute to plaque destabilization and
that subsequent rupture of the fibrous cap triggers thrombus formation. Because the patho‐
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physiology underlying plaque rupture is established [3], the pathophysiology of plaque
erosion and thrombus growth is the focus of this section.
4.1. Possible mechanism of plaque erosion
Eroded plaque is characterized by a superficial plaque injury, but the mechanisms of such
erosions are poorly understood. Approximately 80% thrombi associated with plaque erosion
is nonocclusive regardless of sudden coronary death [16]. Experimental aortic stenosis can
induce acute endothelial changes or damage to the normal aorta [24]. Therefore, hemodynamic
forces, particularly those generated by disturbed blood flow induced by stenosis or vasocon‐
striction, could be a crucial factor in generating surface vascular damage and thrombosis. We
investigated pathological changes after acute luminal narrowing in SMC-rich plaques in
rabbits to understand the relationship between disturbed blood flow and plaque erosion.
Balloon-induced injury of rabbit femoral arteries resulted in the formation of SMC-rich plaques
comprising stellate- or spindle-shaped SMCs and extracellular matrix [25]. Acute vascular
narrowing disrupted the blood flow in these arteries that consequently induced superficial
erosive injury of the SMC-rich plaque. Figure 4 shows microscopic images of a longitudinal
section of neointima at the post-stenotic region 15 min after vascular narrowing. The endo‐
thelial cells and SMCs at this region are broadly detached and associated with platelet adhesion
to the subendothelium and a change in the shape of the SMCs. Endothelial cells and superficial
SMCs became apoptotic within 15 min [26]. Subsequent vascular narrowing induced mural
thrombi comprising platelets and fibrin, as in human plaque erosion. Thus, disrupted blood
flow can induce superficial erosive damage to SMC-rich plaques and subsequent thrombus
formation. We therefore designed a computational fluid simulation using the Reynolds-
averaged Navier–Stokes model and calculated wall shear stress (WSS), turbulence kinetic
energy (TKE), blood pressure, and blood pressure gradients (BPG) in a rabbit model to clarify
the contribution of hemodynamic factors to the onset of plaque erosion in the SMC-rich plaque.
The magnitude of WSS, TKE, and BPG correlated with the extent of histologically defined
erosive damage. The values for WSS and TKE were significantly larger at eroded, than at
noneroded sites [27]. Although direct clinical evidence has not supported the notion that
coronary artery vasospasm plays a role in plaque erosion, ergonovine and norepinephrine-
stimulated vasospasm of the atherosclerotic coronary artery has induced superficially
damaged plaques and acute ischemic injury to the myocardium of a strain of Watanabe
heritable hyperlipidemic rabbits that are prone to myocardial infarction [28]. Platelet and blood
coagulation are activated in the coronary circulation after vasospastic angina [29, 30]. Although
additional evidence is needed, hemodynamic factors might play an important role in the
development of plaque erosion.
4.2. Thrombus growth and stability on disrupted plaques
Thrombus growth is considered critical to the onset of clinical events. Vascular wall throm‐
bogenicity, local blood flow, and blood contents regulate thrombus formation, and thus
thrombus growth seems to vary depending on the status of these three regulators. Neverthe‐
less, a thrombogenic atherosclerotic lesion is essential for atherothrombosis.
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The TF is overexpressed and its procoagulant activity is increased in human atherosclerotic
plaques, and macrophages and SMC both express TF in the intima. The TF is more prominent
in fatty streaks and atheromatous plaques than in a human aorta with diffuse intimal thick‐
ening [4]. Vascular wall TF appears to contribute to the size of thrombi on atherosclerotic
lesions. On the other hand, studies in vitro have shown that not only monocytes but also
neutrophils, eosinophils, and even platelets can synthesize TF. Although TF expression by
blood cells remains controversial, monocytes are the only blood cells that are known to
synthesize and express TF [31]. Plasma TF levels are elevated in patients with unstable angina
and AMI and correlate with adverse outcomes [32]. Hematopoietic cell-derived, TF-positive
microparticles contribute to laser injury-induced thrombosis in the microvasculature of the
mouse cremaster muscle [33]. In contrast, vascular smooth muscle-derived TF contributes to
thrombosis-induced FeCl3 in the mouse carotid artery [34]. Therefore, whether vascular wall
and/or blood-derived TF support thrombus propagation is controversial. We compared the
contribution of plaques and/or blood TF with thrombus formation in the rabbit femoral artery
with or without atherosclerotic lesions induced by a diet containing 0.5% cholesterol and
balloon injury. We found TF expression and increased procoagulant activity in the athero‐
sclerotic arteries compared with the normal femoral arteries. Balloon injury of the atheroscler‐
otic plaque induced thrombin-dependent, large thrombi composed of platelet–fibrin. In
contrast, balloon injury of normal femoral arteries induced thrombin-independent small
platelet thrombi (Figure 5). Moreover, the whole-blood coagulation in rabbits was not affected
by inhibiting the blood TF even under hyperlipidemic conditions [35]. Therefore, at least,
atherosclerotic plaque-derived TF contributes to the activation of the intravascular coagulation
cascade and to thrombus size on atherosclerotic lesions.
The tissue factor pathway inhibitor and argatroban, a thrombin inhibitor, reduce both platelet
and fibrin content in atherosclerotic arteries but not in normal femoral arteries [35]. Oral-
activated factor X (FXa) inhibitors significantly reduce the atherothrombus growth induced
by balloon injury and vascular ligation in rabbits, and plasma FXa activity correlates with the
antithrombotic effects of the oral FXa inhibitors [36]. These findings indicate that excess
A
50m
CB
50m 50m
Figure 4. Representative images of the superficial erosive injury of SMC-rich plaques and thrombus formation. Smooth
muscle cell-rich plaque 15 min after vascular narrowing shows endothelial detachment (small arrows) accompanied by
platelet adhesion (arrow heads) at 1 mm from a region of vascular narrowing (A, hematoxylin eosin stain). Larger ar‐
row indicates flow direction. Immunohistochemistry for VWF (marker of endothelium; B) and smooth muscle actin
(marker of SMC; C) confirms detached endothelial cells and SMCs at the post-stenotic region (from Ref. 26).
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thrombin generation via FXa contributes to further platelet accumulation and fibrin formation
on disrupted plaques. The FXa is generated by factor VII (FVII) or activated factor IX. The
feedback activation of factors VIII and XI (FXI) by thrombin amplifies further thrombin
generation through FXI-, FIX-, and FX activation (Figure 6). The intrinsic coagulation pathway
is initiated when the coagulation factor XII (FXII) comes in contact with collagen, nucleic acids
and polyphosphate, high-molecular mass kininogen, and plasma kallikrein. Factor XI is
activated by activated FXII, thrombin, and activated XI (FXIa) in vitro [37]; it is present in
platelet–fibrin thrombus induced by balloon injury of atherosclerotic lesions in rabbits, and
anti-FXI antibody reduces thrombus formation without prolonging bleeding [38]. Factors XI
and FXII do not affect the initial phase of thrombus formation but prevent thrombus shedding
and contribute to thrombus stability on carotid ruptured plaques in ApoE-deficient mice [39,
40]. In contrast, the inhibition of activated FVII participates in the initial stage of thrombus
formation on ruptured plaques [40]. These findings suggest that after plaque disruption, FXII-
and FXI-mediated amplification of thrombin generation plays an important role in thrombus
stability on disrupted plaques. However, a clinical study discovered an inverse relationship
between levels of FXII and risk of myocardial infarction [41]. A deficiency of FXI did not
prevent the development of acute coronary events [42] but reduced the incidence of deep vein
thrombosis and ischemic strokes [43, 44]. The role of the intrinsic coagulation pathway in
atherothrombosis requires further investigation.
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Figure 5. Immunofluorescence images of thrombus on rabbit femoral artery. 
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permission). 
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Figure 5. Immunofluorescence images of thrombus on rabbit femoral artery. Immunofluorescence microphotographs
of thrombi 15 min after balloon injury of a normal femoral artery and of an atherosclerotic plaque under 0.5% choles‐
terol diet. Rows show differential interference contrast images, images stained with fluorescein isothiocyanate-labeled
integrin αIIbβ3 (green), Cy3-labeled fibrin (red), and merged immunofluorescence images. Areas with colocalized fac‐
tors are stained yellow. Thrombi on normal intima comprise small aggregated platelets (A), whereas large thrombi on
atherosclerotic plaques comprise platelets and fibrin (B). I, intima; IEL, internal elastic lamina, M, media (from Ref. 35,
with permission).
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Figure 6. Exposure of prothrombotic factors and amplification of coagulation cascade on disrupted plaques. Exposure
of the tissue factor, (TF) after plaque disruption, initiates blood coagulation. The activated factor X is generated by acti‐
vated factors VII or IX. Feedback activation of factors VIII and XI by thrombin amplifies further thrombin generation
through sequential activation of factors XI, IX, and X. Factor XI is also activated by intrinsic coagulation factor XII and
activated factor XI. The excess thrombin generation via the feedback activation and intrinsic pathway contributes to
further platelet accumulation and fibrin formation on disrupted plaques. Red square indicates platelet surface.
Platelets comprise a major cellular component in coronary thrombus and play an impor‐
tant role in not only the initial but also the growth phase of thrombus formation. Platelet
recruitment to the thrombus surface and the stabilization of platelet activation are impor‐
tant to maintain platelet accumulation and thrombus growth. Adhesion molecules and their
receptors on platelets are essential for thrombus formation, because they support platelet
tethering and firm adhesion, as well as platelet aggregation and recruitment to the thrombus
surface.  The large,  multimeric,  plasma protein VWF undergoes a conformational change
when bound to extracellular matrix and platelet  surface,  and the conformational change
permits  its  binding  to  GPIbα.  Studies  in  vitro  and  in  vivo  have  shown  that  platelet
recruitment to the thrombus surface is primarily mediated by VWF and GPIbα on flowing
platelets [45, 46]. We found a large amount of VWF localized to coronary thrombi in patients
with AMI [11],  and that a monoclonal antibody against the VWF A1 domain that inter‐
acts with platelet GPIbα, significantly suppresses the formation of platelet–fibrin thrombi
and completely inhibits the occlusive thrombus formation in rabbit atherosclerotic lesions
[25,  47].  These  findings  indicate  that  VWF plays  a  crucial  role  in  thrombus growth via
platelet  recruitment.  Real-time analysis  of  platelet  calcium flux during thrombus forma‐
tion  in  vitro  has  shown  that  the  stable  adhesion  between  aggregated  platelets  and  the
growth of  platelet  thrombus depends on sustained integrin αIIbβ3 activation and cyclic
calcium flux through secreted adenosine diphosphate and its P2Y1 and P2Y12 receptors [48,
49].  We  administer  anti-P2Y12  antagonists  to  prevent  secondary  cardiovascular  events
because these drugs destabilize thrombus and limit thrombus formation.
4.3. Effects of altered blood flow on thrombus growth
Blood flow is a key modulator of thrombus growth, and coronary blood flow is altered in
patients with ischemic heart diseases. Marzilli et al. [50] found that the coronary blood flow is
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reduced by about 80% during ischemia in patients with unstable angina and an autopsy study
frequently found intramyocardial microemboli in patients who succumbed to sudden
coronary death [51]. Distal microvascular embolism and/or vasoconstriction could affect blood
flow as well as thrombus formation and growth at culprit lesions. We examined the effects of
the blood flow reduction on thrombus formation in an animal model and found that > 75%
reduction in blood flow promoted the growth of thrombus consisting of a mixture of platelets
and fibrin on atherosclerotic lesions that subsequently became occlusive, and it also induced
the formation of very small thrombi composed only of platelets on normal arteries [47].
Therefore, a reduction in blood flow associated with increased vascular wall thrombogenicity
is considered to contribute to thrombus growth. We also identified an important role of the 5-
HT2A receptor on platelets and SMCs in this process via platelet aggregation and thrombogenic
vasoconstriction [52, 53].
In addition to distal vascular resistance, blood flow disturbed by acute vascular narrowing
promotes thrombus growth at post-stenotic regions. As described above, vascular narrowing
of the rabbit femoral artery induced superficial erosive injury to SMC-rich plaque. The
progression of neointimal damage caused by disturbed blood flow was associated with
thrombus growth. These findings suggest that the degree of plaque disruption affects throm‐
bus size after the plaque erosion [26].
The rheological effect on thrombus growth might be partly explained by a shear gradient-
dependent mechanism of platelet aggregation. Nesbitt et al. [54] used imaging to reveal a shear
gradient-dependent, platelet-aggregation process that is preceded by the soluble agonist-
dependent aggregation in stenotic microvessels in vitro and in vivo. Shear microgradients at
post-stenotic regions or downstream of thrombi induce stable platelet aggregates, the sizes of
which are directly influenced by shear microgradients. This process requires ligand binding
to integrin αIIbβ3 and transient Ca2+ flux, but does not require a change in global platelet shape
or soluble agonists. These findings suggest that a biomechanical mechanism is principally
involved in the early phase of platelet adhesion and aggregation. Vessel and/or thrombus
geometry itself might promote thrombus formation.
Platelet and/or fibrin aggregates must exceed the physical forces exerted by blood flow within
the narrowing lumen for thrombus to become occlusive and VWF is a candidate in the final
process. The thrombogenic activity of VWF is strictly dependent upon its multimeric structure.
A critical shear stress of 35 ± 3.5 dyn/cm2 induces VWF to change from a globular state to an
extended chain conformation [55]. Such excessive shear stress can induce platelet aggregation
in the absence of exogenous agonists [56], and the interaction between VWF and platelets under
high shear rates might be a key determinant of the final process of thrombotic occlusion. In
fact, inhibiting the plasma VWF completely prevents occlusive thrombus formation induced
by neointimal injury and disrupted blood flow in rabbits [47].
5. Atherometabolism and vascular wall thrombogenicity
Atherosclerotic plaque thrombogenicity is an essential factor for the development of athero‐
thrombosis. However, the determinants of vascular wall thrombogenicity are not yet fully
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understood. Understanding the factors that reflect vascular wall thrombogenicity will allow
the detection of high-risk plaques and the development of novel therapies for atherosclerosis
that target vascular thrombogenicity.
Metabolism in higher animals including humans is finely regulated by metabolic organs, a
neuroendocrine system, and cellular regulatory mechanisms. Recent studies have found that
distinct metabolic states maintain the functions of cancerous and inflammatory cells within
specific microenvironments [57, 58]. Because enhanced glucose metabolism has been visual‐
ized by 18F-FDG-PET in some atherosclerotic lesions, we speculate that the metabolically active
plaque is highly thrombogenic. Therefore, this section focuses on atherometabolism and
vascular wall thrombogenicity.
5.1. Glucose uptake reflects vascular wall thrombogenicity
Although recent advances in clinical imaging have revealed detailed anatomical information
about atherosclerotic lesions, functional information remains limited. The uptake of 18F-FDG
in atherosclerosis closely correlates with macrophage contents in rabbits [7]. Clinical studies
have also found a relationship between 18F-FDG uptake and future cardiovascular events [9,
59]. Thus, the evidence implies an association between 18F-FDG uptake and arterial thrombus
formation. We therefore visualized rabbit atherosclerotic and contralateral nonatherosclerotic
femoral arteries using 18F-FDG-PET, and induced arterial thrombus by balloon injury. The
images revealed more radioactivity along the atherosclerotic than along the contralateral
nonatherosclerotic artery. Areas of arterial thrombus correlated with the amount of arterial
radioactivity determined from the PET images and autoradiography. The amount of arterial
radioactivity positively correlated with macrophage contents, TF expression, and the nuclear
localization of NF-κB, a transcriptional factor of TF. Inhibiting NF-κB reduced TF expression
in rabbit atherosclerotic plaques cultured in vitro [60]. In addition, more 18F-FDG is taken up
by advanced atherosclerotic segments with thrombus induced by Russell’s viper venom and
histamine compared with segments without thrombus in the rabbit aorta [10]. An imaging
study using apoE-deficient mice showed colocalization of deoxyglucose and annexin A5,
which binds phosphatidyl serine, a thrombogenic lipid, on the cell membrane in macrophage-
rich atherosclerotic lesions in mice [61]. Studies of human coronary arteries using 18F-FDG-PET
are limited due to cardiac 18F-FDG uptake. A clinical study has demonstrated higher 18F-FDG
uptake in culprit lesions associated with acute coronary thrombosis compared with stable
coronary lesions in patients with ischemic heart disease [62]. These lines of evidence might
support the notion that arterial glucose uptake reflects plaque thrombogenicity and 18F-FDG-
PET is a minimally invasive method of detecting highly thrombogenic plaques.
5.2. Metabolism in atherosclerotic arteries
Cells uptake 18F-FDG through glucose transporters and phosphorylate it by hexokinases.
Thereafter, intracellular 18F-FDG accumulates without further metabolism and is thus consid‐
ered a marker of glucose utilization in tissues. Although systemic metabolic disorders such as
dyslipidemia and diabetes accelerate the development of atherosclerosis, little is known about
metabolic changes in atherosclerotic arteries and their significance in atherogenesis and
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thrombosis. Glucose utilization and O2 consumption are increased in monkey and rabbit
atherosclerotic aortic segments compared with nonatherosclerotic aortic segments [63]. In
contrast, adenosine triphosphate (ATP) depletion in the cores of advanced atherosclerotic
plaques is associated with hypoxic areas in the rabbit aorta [64]. We analyzed levels of central
carbon metabolites in rabbit atherosclerotic arteries using capillary electrophoresis–time-of-
flight mass spectrometry (CE-TOFMS) to determine comprehensive metabolic changes and
hypoxic effects in atherosclerotic arteries. Macrophage-rich or SMC-rich lesions were gener‐
ated by balloon injury in the iliac–femoral arteries of rabbits fed with a 0.5% cholesterol diet
or a conventional diet. The number of proliferative cells increased in macrophage-rich arteries
compared with control and SMC-rich arteries. Metabolites of glycolysis, the pentose phosphate
pathway, the tricarboxylic acid cycle, and nucleotides increased in arteries with macrophage-
rich lesions compared with noninjured control arteries and those with SMC-rich lesions [65]
(Figure 7).
Hypoxic areas visualized by immunostaining pimonidazole hydrochloride were detectable
only in arteries with macrophage-rich lesions, and they positively correlated with vascular
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18F-FDG uptake. The hypoxic areas were localized deep in the wall, and distributed in
macrophage-rich areas with nuclear localization of hypoxia-inducible factor (HIF)-1α and
hexokinase II expression [65] (Figure 8). Hypoxic responses might partly affect the glycolytic
activity in macrophage-rich arteries. The cores of more advanced plaques > 500 μm thick were
necrotic and hypoxic, and characterized by ATP depletion, low glucose and glycogen concen‐
trations, and high lactate concentrations in the rabbit aorta [64]. The depletion of ATP might
contribute to macrophage death and expansion of the necrotic core in atherosclerotic lesions.
A hypoxic plaque has been detected in the rabbit atherosclerotic aorta using 18F-fluoromiso‐
nidazole PET imaging [66]. Higher 18F-fluoromisonidazole uptake by advanced atherosclerotic
lesions is associated with hypoxic areas and neovascularization.
The pentose phosphate pathway is an alternative route for glucose catabolism that functions
in the formation of ribose 5-phosphate (R5P) that is required for ribonucleic and deoxyribo‐
nucleic acid synthesis for cell growth and proliferation, and the formation of nicotinamide
adenine dinucleotide phosphate (NADPH) for biosynthetic reactions. NADPH protects
directly against oxidative stress by neutralizing reactive oxygen intermediates and indirectly
via regenerating reduced glutathione. Studies have found both small and large amounts of
metabolic flow through the pentose phosphate pathway in arteries compared with the 12
associated with hypoxic areas and neovascularization.  
 
Figure 8. Immunohistochemical findings of hypoxia-inducible factor (HIF)-1 and hexokinase (HK)-II in iliac–femoral artery 
with macrophage-rich lesion. 
Immunohistochemical staining for macrophages, pimonidazole and HIF-1 in paraffin sections (A) and for macrophages, 
pimonidazole and HK-II in frozen sections (B). Nuclear translocation of HIF-1 and expression of HK-II in macrophage-rich 
hypoxic area. Hematoxylin eosin (HE stain) (from Ref. 65). 
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Figure 8. Immunohistochemical findings of hypoxia-inducible factor (HIF)-1α and hexokinase (HK)-II in iliac–femoral
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glycolysis pathway [67, 68]. Increased amounts of metabolites of the pentose phosphate
pathway are compatible with increased nucleotide levels and numbers of proliferative cells in
macrophage-rich arteries [65]. The roles of the pentose phosphate pathway in atherosclerosis
and atherothrombosis are poorly understood. A 20% reduction in normal levels of glucose 6-
phosphate dehydrogenase activity, a key enzyme of pentose phosphate pathway, decreased
serum cholesterol levels, vascular superoxide release, and atherosclerotic lesions but increased
blood pressure in apoE-deficient mice suggest that this pathway exerts complex effects on
atherogenesis [69].
The increase in glycerol 3-phosphate is compatible with increased phospholipid and trigly‐
ceride synthesis in the rabbit atherosclerotic aorta [70]. Atherosclerotic rabbits were injected
with sodium acetate-1-C14 to assess its incorporation into arterial phospholipids. Radioactivity
levels were higher in noncholine-containing phospholipids, phosphatidylcholine, sphingo‐
myelin, and lysolecithin as well as triglycerides in atherosclerotic lesions than in corresponding
plasma phospholipids, whereas < 1% of the label found in the phospholipids was incorporated
into free cholesterol taken up by atherosclerotic lesions [70]. This suggests that phospholipids
and triglycerides are synthesized in atherosclerotic lesions in situ, and that cholesterol is
mainly derived from the plasma. These metabolic changes in atherosclerotic arteries could
partly explain the metabolic changes in activated and/or hypoxic macrophages, as described
below.
5.3. Metabolism of activated and/or hypoxic macrophages
Most cells produce ATP via glycolysis and oxidative phosphorylation under normoxic
conditions, and mainly via glycolysis under hypoxic conditions. However, macrophages
produce ATP via glycolysis even under normoxic conditions. The contributions of glucose,
glutamine, and oleate to ATP production were measured in isolated mouse peritoneal
macrophages using radiolabeled probes. The production of ATP in the macrophages was
mediated by anaerobic glycolysis (54%), aerobic glutamine (24%), and fatty acid oxidation
(22%) [71]. At an initial glucose concentration of 5 mM, almost all utilized glucose was
converted into lactate through glycolysis, whereas only ~3% of glucose was oxidized under
normoxic conditions [72]. The dependence of macrophages on glycolysis might be partly
explained by the impaired HIF-1 inhibition. The cytoplasmic tail of the membrane type-1
matrix metalloprotease bound to factor inhibiting HIF-1 (FIH-1) leads to the inhibition of the
FIH by the adaptor protein Mint3/APBA3 under normoxic conditions [73]. Because most of
the genes related to glycolysis, such as those for glucose transporter 1, hexokinase, phospho‐
fructokinase, phosphoglycerate kinase 1, are induced by HIF-1, the constitutive activation of
HIF-1 might enhance the glycolysis pathway in normoxic macrophages. However, HIF-1α was
translocated to the nucleus mainly in hypoxic areas but not in all macrophages in rabbit
atherosclerotic lesions. Therefore, HIF-1-dependent and -independent pathways might
contribute to the enhanced glycolytic pathway in macrophages in atherosclerotic lesions.
Macrophages comprise a heterogeneous cell population in terms of protein expression and
function, both of which are affected by the microenvironment, and the metabolic status is also
affected by macrophage activation pathways. Classical activation by lipopolysaccharide (LPS)
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and/or interferon-γ enhances the glycolysis pathway and lactate production, whereas an
alternative pathway (interleukin-4 and -13) enhances fatty acid oxidation [74–76]. Hypoxia,
but not pro-inflammatory cytokines, notably stimulates glucose uptake in human macrophag‐
es and foam cells, whereas pro-inflammatory cytokines stimulate glucose uptake in SMCs and
endothelial cells [77]. We analyzed levels of 110 cationic and anionic metabolites in classically
activated THP-1 macrophages under normoxic and hypoxic (1% O2) conditions to determine
comprehensive metabolic changes in macrophages. Under normoxic conditions, one-third of
metabolite levels differed in the macrophages stimulated by lipopolysaccharides and inter‐
feron-γ, while metabolites of the glycolysis and pentose phosphate pathways did not increase
in activated macrophages compared with nonstimulated macrophages. Hypoxia increased
metabolite levels of glycolysis and the pentose phosphate pathway and decreased metabolite
levels of tricarboxylic acid cycle in the activated macrophages. The results of a comprehensive
metabolic analysis support the notion that hypoxia augments glucose utilization through the
glycolysis and pentose phosphate pathways in classically activated macrophages [65]. This
study suggested that metabolic changes occur in nucleotides, amino acids, and other charged
metabolites in classically activated hypoxic macrophages.
Hypoxia also affects lipid metabolism in macrophages and foam cell formation. Increases of
50% and 120% in cholesterol and triglyceride contents, respectively, under hypoxic conditions
(1% O2), were accompanied by elevated 3-hydroxy-3-methyl-glutaryl-CoA reductase activi‐
ties. Cholesterol-efflux assays showed that hypoxia significantly decreased the efflux mediated
by the subcellular distribution of the ATP-binding cassette subfamily A member 1 (ABCA1).
The hypoxia-induced accumulation of sterol and decreased cholesterol efflux was partly
mediated by HIF-1α [78]. Other pathways might also contribute to the lipid metabolism in
hypoxic macrophages. Cholesterol efflux mediated by ABCA1 is regulated by HIF-1β in
primary human macrophages under hypoxia [79]. Positive interaction between liver X receptor
α and HIF-1α synergistically induces triglyceride accumulation and foam cell formation in
human primary macrophages and RAW 264.7 cells under hypoxia [80]. The expression of the
secreted proteoglycan, versican, is enhanced in hypoxic macrophages, which might increase
lipoprotein retention in microenvironments as well as the lipid content of hypoxic macro‐
phages [81].
Changes in metabolism or in metabolites can alter the inflammatory response of activated
macrophages. The heterozygous disruption of inducible 6-phosphofructo-2-kinase, a rate-
limiting glycolysis enzyme, enhances pro-inflammatory gene expression in adipose tissue
macrophages  from mice fed with a  high-fat  diet  [82].  A kinase  screening has  identified
downregulation of sedoheptulose kinase, an enzyme of the pentose phosphate pathway, in
LPS-stimulated  RAW  264.7  macrophages.  The  reduction  of  sedoheptulose  kinase  in
activated macrophages is  associated with greater  flux through glycolysis  and the oxida‐
tive pentose phosphate pathway, which results in an increased overall redox potential and
a  reduced  rate  of  O2  consumption  [83].  The  overexpression  of  glucose-6-phosphate
dehydrogenase,  the  first  and  rate-limiting  enzyme  of  the  pentose  phosphate  pathway,
stimulates NF-κB transcriptional activity and promotes oxidative stress and inflammatory
responses  in  RAW  264.7  macrophages  [84].  These  findings  suggest  cross  talk  between
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macrophage  activation  pathways  and  metabolism.  With  respect  to  atherogenesis,  a
deficiency of fatty acid synthase or a long-chain fatty acid elongase reduces atherosclero‐
sis in apoE- or low-density receptor-deficient mice [85, 86].
5.4. Hypoxia links atherometabolism to vascular thrombogenicity
Arterial glucose uptake reflects vascular thrombogenicity in rabbits [60]. However, the
underlying mechanisms remain unclear. Hypoxia is an important microenvironmental factor
that influences the progression of atherosclerosis by inducing foam cell formation and necrotic
core expansion, metabolic changes in infiltrative macrophages, and plaque neovascularization.
Sluimer et al. [87] used the hypoxia marker pimonidazole hydrochloride to reveal hypoxic
areas in the center of an advanced human carotid plaque and found that they correlated with
the presence of thrombus, angiogenesis, microvessel density and the expression of hexokinase,
HIF, and vascular endothelial growth factor. Hypoxia upregulates TF in the lungs [88],
plasminogen activator inhibitor (PAI)-1 in hepatocytes [89], and ecto-nucleoside triphosphate
diphosphohydrolase 1 (ecto-NTPDase 1) expression in endothelial cells [90]. TF and PAI-1
promote fibrin formation by initiating the coagulation cascade and inhibiting fibrinolysis,
respectively, whereas ecto-NTPDase inhibits platelet aggregation via the hydrolysis of
extracellular adenosine diphosphate. Because these three molecules are expressed in human
atherosclerotic plaques [4, 91, 92], hypoxic conditions in the plaques can affect vascular
thrombogenicity and arterial thrombus formation. We examined the effects of hypoxia in
arterial thrombus formation using rabbit model of atherosclerosis, atherothrombosis, cultured
macrophages, and human coronary plaques with or without acute coronary thrombosis.
Atherosclerotic lesions were induced in rabbit femoral arteries by a 0.5%-cholesterol diet and
balloon injury. Hypoxic areas detected by pimonidazole immunoreactivity were localized in
the lipid and macrophage-rich deep portions of the plaque and a few superficial cells, but not
in uninjured arteries. The extent of the hypoxic areas correlated with the plaque size, macro‐
phage content, the nuclear localization of HIF-1α and NF-κB p65, and TF expression. Hypoxic
areas in arteries closely correlated with fibrin areas in thrombus induced by a balloon catheter
and hypoxia (1% O2) enhanced the nuclear localization of HIF-1α and NF-κB p65, as well as
TF expression and procoagulant activity in cultured macrophages [93]. The enhanced TF
activity was suppressed by the inhibitors of either HIF-1 or NF-κB, suggesting that HIF-1 and
NF-κB exert synergic effects upon procoagulant activities in hypoxic plaques [93]. These
findings suggested that hypoxia promotes arterial fibrin formation via the augmentation of
vascular thrombogenicity in rabbits. Coronary plaques contain more abundant macrophages,
T lymphocytes, and fibrin deposition in patients with unstable angina pectoris than in patients
with stable angina pectoris. The expression of TF, PAI-1, HIF-1α, and NF-κB p65 is closely
distributed in coronary thrombotic plaques, and the nuclear localization of HIF-1α correlates
with the expression of NF-κB p65, TF, PAI-1, and fibrin [93]. The pathological findings support
the notion that hypoxic and nonhypoxic, possibly inflammatory, stimuli enhance thromboge‐
nicity in symptomatic plaques. Because hypoxia enhances glucose uptake and glycolysis flux
in atherosclerotic lesions and macrophages as described above, hypoxia might link glucose
metabolism and thrombogenicity in atherosclerotic plaques.
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6. Conclusion
The pathological findings suggest that the enhanced platelet aggregation and fibrin formation
result in occlusive thrombus formation on disrupted atherosclerotic plaques. The size of the
arterial thrombus would be affected by the degree of plaque disruption, the amount of exposed
TF and platelet agonists, changes in blood flow, and the geographic features of disrupted
plaques. Disrupted blood flow and excess thrombin generation can amplify blood coagulation
and platelet recruitment to the thrombus surface and sustain platelet activation. Arterial
glucose uptake reflects vascular thrombogenicity. These findings might be partly explained
by metabolic adaptation and enhanced procoagulant activity under a hypoxic microenviron‐
ment, although further study is required. The relationship might provide new insight into
novel therapeutic targets for atherothrombosis and the noninvasive detection of high-risk
plaques.
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